Drug repurposing screening identified tropifexor as a SARS-CoV-2 papain-like protease inhibitor
Authors:
Preprint
Abstract
The global COVID-19 pandemic underscores the dire need of effective antivirals. Encouraging progress has been made in developing small molecule inhibitors targeting the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and main protease (M pro ). However, the development of papain-like protease (PL pro ) inhibitors faces several obstacles. Nevertheless, PL pro represents a high-profile drug target given its multifaceted roles in viral replication. PL pro is involved in not only the cleavage of viral polyprotein but also modulation of host immune response. In this study, we conducted a drug-repurposing screening of PL pro against the MedChemExpress bioactive compound library and identified three hits, EACC, KY-226, and tropifexor, as potent PL pro inhibitors with IC 50 values ranging from 3.39 to 8.28 µM. The three hits showed dose-dependent binding to PL pro in the thermal shift assay. In addition, tropifexor inhibited the cellular PL pro activity in the FlipGFP assay with an IC 50 of 10.6 µM. Gratifyingly, tropifexor showed antiviral activity against SARS-CoV-2 in Calu-3 cells with an EC 50 of 4.03 µM, a 7.8-fold increase compared to GRL0617 (EC 50 = 31.4 µM). Overall, tropifexor represents a novel PL pro inhibitor that can be further developed as SARS-CoV-2 antivirals.Keywords
All Related Versions
- Published version: ACS Infectious Diseases, 8 (5), 1022.
This publication has 30 references indexed in Scilit:
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Papain-like protease regulates SARS-CoV-2 viral spread and innate immunityNature, 2020
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main proteaseCell Research, 2020
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in miceScience Translational Medicine, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)2017
- The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compoundsAntiviral Research, 2015
- Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating Activity of SARS-CoV Papain-Like ProteasePLOS Pathogens, 2014
- X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like ProteasesJournal of Medicinal Chemistry, 2014
- Specific Binding of Adamantane Drugs and Direction of Their Polar Amines in the Pore of the Influenza M2 Transmembrane Domain in Lipid Bilayers and Dodecylphosphocholine Micelles Determined by NMR SpectroscopyJournal of the American Chemical Society, 2011